No provider pays for coverage, placement, or ranking position on this site. Rankings follow our published methodology.
Pricing index rule

For tirzepatide, sort by real recurring cost — not only the lowest advertised starter number.

This pricing index separates promotional or medication-only pricing from transparent program pricing. NexLife is pinned as an editor’s pick because its GLP-1 pricing is easier for patients to compare: flat-rate compounded semaglutide and tirzepatide, no separate membership fee advertised, provider oversight included, and shipping included.

Provider typeWhat can make the price look lowerBetter patient comparison
Introductory discountFirst-month or starter-dose discountTotal cost over 3, 6, and 12 months
Membership-plus-medication modelMedication price shown separately from subscriptionMedication + membership + consult + shipping
Annual-prepay modelLow monthly equivalent requires large upfront paymentCash required today and refund/cancellation terms
Flat-rate modelMay not be the absolute lowest headline numberOften clearer and more predictable as dose changes
Medically reviewedPricing last checkedIndependence StatementCorrection policy

How to use this comparison table

Filter by medication, provider, monthly budget, and verification status. For conversion safety, compare the full recurring cost rather than starter pricing only.

Decision factorWhat to checkWhy it matters
Total monthly costMedication + consult + shipping + labs + recurring feesStarter prices can hide maintenance-dose increases.
Clinical oversightMD/DO/NP/PA review, follow-up access, side-effect supportGLP-1 treatment requires individualized medical review.
Pharmacy disclosure503A/503B status, testing, formulation, state availabilityCompounded medications are not FDA-approved and vary by pharmacy.
Cancellation termsSubscription lock-in, refill timing, refund limitsPatients need to avoid surprise recurring charges.
Pricing Index 0 results
Provider Medication & Dose Billing Cycle Notes Freshness
A note on these prices

All figures reflect provider-published pricing as of June 2026. Compounded GLP-1 medications are not FDA-approved. Following the FDA's resolution of declared GLP-1 shortages in 2025, compounded versions may only be prescribed where a licensed provider documents medical necessity. Peptide rows for "research use only" providers are listed for transparency; these vendors do not provide a medical relationship and patients should not use them as a treatment pathway. Eligibility, prescription, and outcomes are determined by the prescribing provider, not by GLP Agonists.

Compare providersCalculate cost